Last reviewed · How we verify
Levodopa administration
At a glance
| Generic name | Levodopa administration |
|---|---|
| Also known as | Madopar® tablets (Levodopa and Berazidhydrochlorid; Roche) |
| Sponsor | University Hospital Tuebingen |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
- Nausea
- Somnolence
- Yawning
- Fall
- Dizziness
- Dyskinesia
- Oral mucosal erythema
- Fatigue
- Headache
- Mouth ulceration
- Lip swelling
- Orthostatic hypotension
Key clinical trials
- Dopamine Modulation of Motivation and Motor Function in Major Depression & Inflammation (NA)
- An Investigational Scan (18F-DOPA PET/CT) for Improving the Clinical Management of Brain Tumors (PHASE2)
- Clinical Study to Evaluate the Possible Efficacy of Metformin in Patients With Parkinson's Disease (PHASE2)
- Intestinal Levodopa + Entacapone Therapy (Lecigon®) to Counteract Dopaminergic Desensitization and Neuropsychiatric Complications in Parkinson's Disease (PHASE3)
- Udall Project 2 Aim 2A&C
- Levodopa for Diabetic Retinopathy (PHASE2)
- A Late Phase II Clinical Trial of KDT-3594 in Patients With Parkinson's Disease (PHASE2)
- REal-life ON PARKinson's - ITaly (REONPARK-IT)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |